Helen Albert, Author at Labiotech.eu

About

Freelance science and health journalist with lots of experience writing about all aspects of life sciences and biotech. Recovering geneticist and evolutionary biologist. I am half German and half British and spend most of my time in Berlin while not hiding out in the Norfolk countryside in the UK. When not writing or editing, I like to spend my time taking photos, knitting, reading fiction, eating and making good food and travelling (when global conditions allow!).

Articles by Helen Albert

News and Trends 3 Sep 2019

Gyroscope Targets Age-Related Blindness with €55M Series B

UK gene therapy biotech Gyroscope Therapeutics has secured €55.4M in Series B funding to target age-related macular degeneration. Life sciences investor Syncona, which is backed by the UK’s Wellcome Trust, continued its support of the company contributing €52.7M to the round. This brings its total investment in Gyroscope to €90M since the biotech was founded […]

September 3, 2019 - 2 minutesmins - By Helen Albert

Nabriva story bacterial pneumonia antibiotic

News and Trends 20 Aug 2019

Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic

The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of antibiotics developed to treat this condition. Xenleta, also known as lefamulin, was discovered almost 10 years ago by Nabriva Therapeutics, a spinout company from Novartis split between Austria, Ireland and the US. The approval is […]

August 20, 2019 - 3 minutesmins - By Helen Albert

Best in Biotech 13 Aug 2019

10 Biotech Books Recommended by Labiotech Readers

To help you enjoy the summer, here is a list of book suggestions for you to take with you on your travels, as recommended by our readers. We asked the Labiotech team what they liked to read last year and we had a great response to the article from our online community. This year we […]

August 13, 2019 - 9 minutesmins - By Helen Albert

Expert Advice 7 Aug 2019

Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience

In less than two years, Orchard Therapeutics has changed from a small, relatively unknown UK biotech specializing in gene therapy into a billion euro company listed on the Nasdaq. This is in no small part due to the skills and experience of Mark Rothera, its CEO and President, who joined the company in 2017. Orchard […]

August 7, 2019 - 13 minutesmins - By Helen Albert

Interview 30 Jul 2019

The First Approved NASH Therapy?

Genfit is poised to become the first company to get a treatment for NASH to market — something that could happen as early as 2020, should its late 2019 phase III trial results be positive. I spoke to Dean Hum, the current COO and CSO of Genfit, to find out more about the company’s 20-year […]

July 30, 2019 - 6 minutesmins - By Helen Albert

More News! 27 Jun 2019

German Biotech Will Target Parkinsonian Disorders with €12M Series A

Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s […]

June 27, 2019 - 2 minutesmins - By Helen Albert

Expert Advice 8 Jun 2019

Why Sticking to Your Beliefs is Important for Biotech Success

Galapagos is an undeniable success story. Set up in 1999, it is now one of the largest and most successful biotechs in Europe. A key driving force behind the company is Onno van de Stolpe, its founder and CEO. After doing an internship at Biogen while at university, van de Stolpe knew he wanted to […]

June 8, 2019 - 11 minutesmins - By Helen Albert

Interview 23 May 2019

Why Clinical Trial Design Can Make or Break Your Company

Andreas Wallnöfer spent over 20 years working on drug development at Roche before moving to BioMedPartners to apply his expertise to biotech investment. At our recent Labiotech Refresh event in Zurich, he explained why good clinical trial design can be key to a biotech’s success. Wallnöfer was one of the pioneers of ‘proof of concept’ […]

May 23, 2019 - 7 minutesmins - By Helen Albert

News and Trends 20 May 2019

UK Immune Cell Therapy Biotech Founded with €40M Series A

Quell Therapeutics, a London-based biotech developing immune cell therapies to target transplant rejection and autoimmune and inflammatory diseases, launched today with €40M series A funding. UK life sciences trust Syncona is the lead investor, with a €38.8M stake in the company. Syncona will own a controlling 69% of the business, reflecting their large initial investment. […]

May 20, 2019 - 2 minutesmins - By Helen Albert

News and Trends 20 May 2019

Update: British RNA Biotech Increases Series A to €34M

Update (20/05/19): Storm Therapeutics has increased its series A financing round by an additional €16M (£14M) to €34M (£30M), which the company plans to use to advance its pipeline of RNA focused drug candidates towards the clinic. Seroba Life Sciences, an Irish VC focusing on new and innovative therapies, is the key new investor. Existing […]

May 20, 2019 - 2 minutesmins - By Helen Albert

biontech cancer vaccine mrna immunotherapy

Interview 13 May 2019

Putting DNA Repair on the Map

Niall Martin is on a mission to put DNA repair on the map. He has already gone pretty far along the way to doing this, as the leader of the team that developed the blockbuster cancer drug Lynparza. He is now seeking to repeat this early success at Artios, where he is CEO. Martin talked […]

May 13, 2019 - 8 minutesmins - By Helen Albert

Expert Advice 8 May 2019

Why It’s Important to “Think Big” When Raising Money for Your Company

There are not many people who can say they led one of Europe’s largest biotechs and launched the first approved gene therapy in Europe. Joern Aldag, now CEO at Austrian biotech Hookipa Pharma, has done both. Aldag got into biotech because he wanted to use his entrepreneurial skills to advance medicine. After 9 years of […]

May 8, 2019 - 9 minutesmins - By Helen Albert

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Helen Albert

About

Articles by Helen Albert

Gyroscope Targets Age-Related Blindness with €55M Series B

Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic

10 Biotech Books Recommended by Labiotech Readers

Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience

The First Approved NASH Therapy?

German Biotech Will Target Parkinsonian Disorders with €12M Series A

Why Sticking to Your Beliefs is Important for Biotech Success

Why Clinical Trial Design Can Make or Break Your Company

UK Immune Cell Therapy Biotech Founded with €40M Series A

Update: British RNA Biotech Increases Series A to €34M

Putting DNA Repair on the Map

Why It’s Important to “Think Big” When Raising Money for Your Company

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Helen Albert

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!